---
schema_version: "secwatch.filing_event.v1"
accession: "0001438533-26-000046"
form_type: "8-K"
ticker: "TVTX"
cik: "0001438533"
company_name: "Travere Therapeutics, Inc."
filed_at: "2026-05-21T20:07:19+00:00"
generated_at: "2026-05-21T22:20:50.084525+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Travere shareholders approve 3M share increase under 2018 equity plan

## Summary
- Stockholders approved amendment to 2018 Plan, increasing authorized shares by 3,000,000 shares.
- Ten directors elected to serve until 2027 annual meeting; all received majority votes.
- Advisory say-on-pay resolution passed with 73.7M votes for (97.3% of votes cast).
- Shareholders ratified Ernst & Young as independent auditor for fiscal year 2026.
- Annual meeting held May 19, 2026; 81.1M shares (88% of outstanding) were represented.

## SEC filing metadata
- accession: 0001438533-26-000046
- form_type: 8-K
- ticker: TVTX
- cik: 0001438533
- company_name: Travere Therapeutics, Inc.
- filed_at: 2026-05-21T20:07:19+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 5.02, 5.07, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1438533/000143853326000046/0001438533-26-000046-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1438533/000143853326000046/tvtx-20260519.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001438533-26-000046
- JSON: https://secwatch.observer/filing/0001438533-26-000046.json
- Plain text: https://secwatch.observer/filing/0001438533-26-000046.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.